Competition Coming For Hemophilia Franchises, But Will Patients And Payers Embrace New Drugs?

Roche's emicizumab, Alnylam's fitusiran and multiple gene therapies may soon steal market share from established clotting factors sold by Shire, Novo Nordisk and others, but safety is a key consideration for physicians and patients.

Hemophilia patients are loyal to brand-name clotting factors that have enjoyed market dominance for many years, but a shakeup may be coming in the form of monoclonal antibodies, RNA-based treatments and gene therapies if safety factors and treatment durability don't get in the way.

Shire PLC has the world's largest hemophilia franchise following its acquisition of Baxalta Inc., generating more than twice...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Blood and Clotting

More from Therapeutic Category